Aerie's glaucoma drug Rocklatan (netarsudil/latanoprost) gets FDA approval

,
a
of the http:// ( http://announced that the U.SFood andMedicines(http://Administration (
FDA(http://) had approved the company's glauselsud/latanoprost eye solution, 0.02%/0.005 percentRocklatan is a daily eye drop that reduces intra-eye pressure (IOP) in patients with open-angle glaucoma or high eye pressureAerie has plans to bring Rocklatan to market in the second quarter of 2019RocklatanRocklatan consists of fixed doses of latanoprost and netarsudil, of which: Latanproprosin is one of the most widely prescribed prostaglandin analogues (PGA), through the grape membrane scloraic al-Pathway The mechanism increases fluid flow, and netarsudil is the active pharmaceutical ingredient of Aerie's listed glaucoma drug Rhopressa (netarsudil eye solution, 0.02%), a first-ever Rho kinase (ROCK) inhibitor specifically designed for eye girder nets 　　Rocklatan is Aerie's second FDA-approved glaucoma drug and the first and only daily fixed-dose PGA and ROCK inhibitor combination product (http:// Clinical data show that Rocklatan's efficacy is statistically significantly superior to that of the widely used glaucoma Rocklatan, based on data from two Phase III clinical studies (MERCURY 1, MERCYRY 2) In these studies, Rocklatan achieved the main 90-day end point of efficacy and 12 months of safety and efficacy, showing a more significant reduction in eye pressure at each measurement point in time than lattatamprosin and netarsudil specific data, more than 60 percent of patients in the Rocklatan treatment group achieved a 30% or more reduction in IOP, almost twice as much as in the Lattaprosin treatment group Rocklatan also helped more patients reach low target stress levels, with the ratio of 16mmHg and 14mmHg to almost twice as high as and almost three times that of the Lattaprosin treatment group, respectively 　　In terms of safety
Rocklatan treatment was associated with generally mild and tolerable eye adverse events and had few systemic side effects in 2 studies Rocklatan's most common eye adverse event in controlled clinical studies is conjunctiva congestion Ninety percent of hyperemia patients reported mild congestion, and 5 percent of patients stopped taking drugs because of hyperemia Other common eye side effects reported in studies include pain at the drip site, corneal worm, and conjunctiva bleeding